Search at Vanderbilt-Ingram Cancer Center

1262 results found

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Relevance: 1

Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial

Relevance: 1

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery [ERASUR]

Relevance: 1

An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

Relevance: 1

An Open-Label, Phase 1a/1b, Dose Escalation and Dose Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PHST001 in Adult Patients with Advanced Relapsed and/or Refractory Solid Tumors

Relevance: 1

An Open-Label, Randomized Study of BMS-986489 (Atigotatug + Nivolumab Fixed-Dose Combination) vs Durvalumab as Consolidation Therapy Following Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (TIGOS-LS)

Relevance: 1

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Relevance: 1

A Phase I, Open Label Single-Arm Two-Part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subjects with Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and with Other Solid Tumors

Relevance: 1

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

Relevance: 1

A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody, Versus Investigator's Choice in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-1)

Relevance: 1